[HTML][HTML] Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy
M Sabatino, S Kim-Schulze, MC Panelli… - Journal of clinical …, 2009 - ncbi.nlm.nih.gov
M Sabatino, S Kim-Schulze, MC Panelli, D Stroncek, E Wang, B Taback, DW Kim…
Journal of clinical oncology, 2009•ncbi.nlm.nih.govSerum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to
High-Dose Interleukin-2 Therapy - PMC Back to Top Skip to main content NIH NLM Logo
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC
Full-Text Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol
PMC2689845 Other Formats PDF (566K) Actions Cite Collections Share Permalink Copy
RESOURCES Similar articles Cited by other articles Links to NCBI Databases Journal List J Clin …
High-Dose Interleukin-2 Therapy - PMC Back to Top Skip to main content NIH NLM Logo
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC
Full-Text Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol
PMC2689845 Other Formats PDF (566K) Actions Cite Collections Share Permalink Copy
RESOURCES Similar articles Cited by other articles Links to NCBI Databases Journal List J Clin …
Abstract
Purpose
High-dose interleukin-2 (IL-2) induces durable therapeutic responses in a small subset of patients with metastatic melanoma and renal cell carcinoma, but simple pretreatment predictors of response have not been identified.
ncbi.nlm.nih.gov